Today begins a new chapter for GRAIL as an independent, publicly traded company. We will be listed under $GRAL on Nasdaq as of the market open June 25. Learn more: https://bit.ly/3S4T1H9
GRAIL
Biotechnology Research
Menlo Park, CA 86,212 followers
Detect cancer early, when it can be cured.
About us
Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care. We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges. GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit grail.com. Community Guidelines: https://bit.ly/3xigb24
- Website
-
http://www.grail.com
External link for GRAIL
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Menlo Park, CA
- Type
- Privately Held
- Founded
- 2016
- Specialties
- Cancer Detection, Cancer Biology, Clinical Trials, Computer Science, Machine Learning, and Data Science
Locations
-
Primary
1525 O'Brien Drive
Menlo Park, CA 94025, US
Employees at GRAIL
Updates
-
📣 We are thrilled to announce Susanna Quinn is joining The Cancer SIGNAL podcast as our new host! As a cancer survivor, entrepreneur, writer and philanthropist, Susanna will bring her experience and perspectives to these conversations around early cancer detection. Subscribe now to get notifications for new episodes! https://bit.ly/4c42Mwb #HealthCarePodcast #CancerEducation
-
-
Our talented summer interns are making a real impact across various departments, while also finding time to give back to their communities. We are incredibly proud of their achievements and grateful for their dedication in driving innovative projects forward. #GRAILproud #Internship
-
-
Novel cancer screening technologies, like multi-cancer early detection (MCED) tests, hold great promise for reducing the burden of late-stage cancers and related cancer mortality, but new approaches are required to evaluate their effectiveness. Sir Harpal Kumar, President of GRAIL Europe, shares his perspective in Molecular Oncology as to why innovative trial designs with earlier endpoints are needed to demonstrate the potential benefits of novel screening technologies, like MCEDs, more rapidly. Read the publication to learn more: https://bit.ly/4c0C7jG
-
-
When Valerie first read about multi-cancer early detection testing she became intrigued by its potential. Even though she felt healthy, she decided to get tested. Her surprising Cancer Signal Detected result led to follow-up exams that helped doctors diagnose her with cancer. Valerie shares how early detection affected her experiences – here: https://bit.ly/4cNAPd6 #CancerScreening
-
Today we’re announcing the first participant enrolled in our Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH) Galleri-Medicare study at Community Health Network. We’re evaluating the clinical impact of our multi-cancer early detection (MCED) test in the Medicare population, including racial and ethnic minorities and seniors from historically under-served communities. The three-year, multi-center study will evaluate and compare up to 50,000 Medicare beneficiaries who have received usual care plus an annual MCED test, in addition to recommended cancer screenings, with others who will not receive an annual MCED test. Medicare will cover the costs of MCED testing and routine items and services for study participants. With more than half of all cancer diagnoses among seniors, our commitment at GRAIL is to provide broad, equitable MCED test access to groups that are at the highest risk and underrepresented in clinical research – including the Medicare population. Read more about the news: https://bit.ly/3Wsdeci
-
-
We are excited to share the Journal of Thoracic Oncology has published a study supporting a methylation-based cell-free DNA assay in a cohort of patients with resectable stage I-II NSCLC. Read more about the findings: https://bit.ly/3WqgKUo
-
-
Clinical trials update: We’ve completed planned enrollment for the PATHFINDER 2 study and the third and final round of study visits for the NHS-Galleri trial. Both studies successfully enrolled a diverse population, with participants representing various socio-economic, ethnic, gender and age groups. Learn more: https://bit.ly/4bDJZHW
-
-
After reading about multi-cancer early detection testing, Roger spoke to his healthcare provider to learn more. Because he had no symptoms, he didn’t expect the news that his test had yielded a Cancer Signal Detected result. Learn how proactive screening changed Roger's #cancer journey: https://bit.ly/3xNV0Zg
-
CEO Bob Ragusa joined proud GRAIL employees in Times Square yesterday to celebrate this significant milestone for our company. #NasdaqListed $GRAL
-